• ARS Pharmaceuticals Chief Commercial Officer Eric Karas exercised options for 25,000 common shares at USD 1.5 on June 12, 2026.
• Karas sold 25,000 common shares at USD 10 on June 12, 2026.
• Directly held common shares fell to 12,176 following the transactions.
• Directly held stock options rose to 519,588 following the exercise.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ARS Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001951287-26-000004), on June 12, 2026, and is solely responsible for the information contained therein.